Blue Cross Blue Shield mandates severe asthma patients self-administer drugs at home, unless their provider gets prior approval from the company.

Drilling down into subgroups of patients, Sanofi also claimed that amlitelimab demonstrated “compelling efficacy” in patients ...

SNY shares preliminary data from phase II study on amlitelimab in moderate-to-severe asthma. It also provides updates on ...

Millions of U.S. children have asthma and benefit from taking anti-inflammatory medications at least once a day as prescribed by their health care provider. This school-based asthma therapy program ...

But for at least one of the drugs, Xolair, the reaction can also happen up to a year into treatment. Many families are not comfortable administering biologics to their kids with severe asthma ...

For millions of people around the world, asthma is more than just a breathing problem—it is a chronic and often debilitating ...

Analysts at Leerink agreed with Sanofi that, despite falling short of statistical significance in the Phase II TIDE-Asthma trial, amlitelimab warrants further development in this indication.

Preliminary Data From SNY's Asthma Study on Amlitelimab Preliminary data from the TIDE-Asthma study showed that treatment with the ... SNY markets blockbuster asthma drug Dupixent (dupilumab ...

Among these, the integration of a Human Design Chart with traditional therapy represents an innovative fusion that’s gaining traction among therapists and clients alike. This unique combination offers ...